Combination Therapy With Dabrafenib and Trametinib for Langerhans Cell Histiocytosis‐Associated Neurodegenerative Disease
- 22 December 2025
- journal article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e70034
Abstract
No abstract availableFunding Information
- Japan Agency for Medical Research and Development (JP23ek0109635)
- Japan Agency for Medical Research and Development (JP23ck0106852)
- Ministry of Health, Labour and Welfare
This publication has 9 references indexed in Scilit:
- BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCHBlood, 2025
- Neurodegeneration in patients with multisystem Langerhans cell histiocytosis treated with vemurafenibBritish Journal of Haematology, 2024
- Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosisBritish Journal of Haematology, 2024
- Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosisBritish Journal of Haematology, 2024
- Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 studyInternational Journal of Hematology, 2023
- Langerhans cell histiocytosisBlood, 2020
- Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibitionBlood, 2019
- Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain MetastasesDrug Metabolism and Disposition, 2014
- Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain MetastasesThe Journal of Pharmacology and Experimental Therapeutics, 2013